Drug Profile
Oxycodone transdermal - Avecho Biotechnology
Alternative Names: Sustained-release oxycodone patch - Avecho Biotechnology; TPM/O patch; TPM/oxycodone patch - Avecho Biotechnology; TPM®/Oxycodone patchLatest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Phosphagenics
- Developer Avecho Biotechnology; Phosphagenics
- Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pain
Highest Development Phases
- Phase II Postherpetic neuralgia
- No development reported Neuropathic pain; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Pain(In volunteers) in Australia (Transdermal, Patch)
- 10 Nov 2016 Phosphagenics extends the term of licence option granted to Terumo under May 2016 agreement
- 16 Feb 2016 No recent reports on development identified - Preclinical for Neuropathic pain in Australia (Topical)